In recent years, a great deal of effort has been devoted to develop precise anti-cancer therapeutics by selectively targeting FGFRs: such as FGFR1-4 inhibitors of futibatinib (TAS-120) [6], derazantinib (ARQ 087) [7], LY2874455 [8], and KIN-3248 [9], and FGFR1-3 inhibitors of AZD4575 [10] and Debio 1347 [11] under clinical development. The gene discussed is FGFR1; the disease is cancer.